Ondine and Mid Yorkshire Teaching NHS Trust shortlisted for Excellence in Healthcare Partnership Award for Reducing Surgical Site Infections with Nasal Photodisinfection Second national award shortlist recognises successful partnership addressing the NHS priority of reducing surgical site infections and antimicrobial resistance. Ondine Biomedical Inc and Mid Yorkshire Teaching NHS Trust [...]

First German Hospital Pilots Steriwave Ondine Biomedical Partners with LMU University Hospital Munich  to Trial Steriwave in ENT Patients Ondine Biomedical Inc. is pleased to announce a significant research collaboration with LMU University Hospital Munich, one of Europe’s most esteemed and highly ranked medical institutions. This partnership marks a pivotal [...]

Ondine shortlisted for HSJ Partnership Award HSJ Partnership Award Finalists: Ondine Biomedical and Mid Yorkshire Teaching NHS Trust for Cutting Post-surgical Infection Rates Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust (Mid Yorks) have been shortlisted for the ‘Most Impactful Use of Technology on Clinical Practice’ award at the [...]

Topline Results Significant in Steriwave ICU Study Steriwave Shows Significant Sustained ICU Pathogen Reduction in Royal Columbian Hospital Study Reinforcing Universal Nasal Decolonisation for Infection Control Steriwave nasal decolonisation study proves pathogen reduction in ICU setting ICU market represents a multi billion-dollar opportunity for Ondine Nasal decolonisation is already Standard [...]

Cambridge’s Papworth Hospital Pilots Steriwave Royal Papworth Hospital Pilots Steriwave to Advance Patient Safety in Complex Cardiac Surgeries Ondine Biomedical Inc. announces that the Royal Papworth Hospital NHS Foundation Trust, one of the world’s foremost cardiothoracic centres, is launching a pilot program with Steriwave® nasal photodisinfection therapy. Developed in collaboration [...]

Steriwave Now Protecting Patients with Cancer The Mater Hospital, North Sydney, Adopts Steriwave to Combat AMR in Cancer Care Antimicrobial resistance (AMR) is driving higher mortality, morbidity, and healthcare costs for patients with cancer. Hospitalized patients with cancer face up to twice the risk of antibiotic-resistant infections. AMR pathogens are [...]

Ondine Presents Major Economic Benefits at ICPIC Analysis Presented at ICPIC 2025 Highlight Benefits of Steriwave Nasal Photodisinfection in Head-to-Head Comparisons with Octenisan and Mupirocin   70% SSI reduction in hip and knee arthroplasties using Steriwave at Mid Yorkshire Hospitals NHS Trust compared to using Octenisan nasal gel alone. 52% [...]

Steriwave Effective Against C. auris C. auris drug resistant fungus has increased by 67% in EU Hospitals year on year VANCOUVER, B.C.— According to a new report this month from the European Centre for Disease Prevention and Control (ECDC) cases of Candidozyma auris (C. auris) formerly known as Candida auris, [...]

Steriwave Featured on CNBC’s Worldwide Exchange Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated, non-antibiotic infection prevention therapies, announces that its Steriwave® nasal photodisinfection technology received international media attention when it was highlighted yesterday on CNBC’s Worldwide Exchange by former President of Mexico, Vicente Fox. During the interview, Mr. [...]